ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.96
0.54%
Dow Jones
39,331.85
0.41%
Gold vs US Dollar
2,339.425
0.40%
Brent Oil
86.37
-0.09%
Bitcoin
60,783.99
-2.00%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Keros Therapeutics Inc (KROS)

  7. Keros Therapeutics Inc (KROS) News

Keros Therapeutics (KROS)

Keros Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KROS
DateTimeSourceHeadlineSymbolCompany
17/06/202422:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
17/06/202422:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KROSKeros Therapeutics Inc
17/06/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
17/06/202421:01GlobeNewswire Inc.Keros Therapeutics Announces Leadership UpdatesNASDAQ:KROSKeros Therapeutics Inc
17/06/202411:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
17/06/202411:00GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
04/06/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
04/06/202413:00GlobeNewswire Inc.Keros Therapeutics to Host a Corporate Update Conference Call and WebcastNASDAQ:KROSKeros Therapeutics Inc
03/06/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
03/06/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
03/06/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
03/06/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
03/06/202413:00GlobeNewswire Inc.Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
30/05/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
28/05/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
28/05/202421:01GlobeNewswire Inc.Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsNASDAQ:KROSKeros Therapeutics Inc
14/05/202415:00GlobeNewswire Inc.Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
08/05/202413:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KROSKeros Therapeutics Inc
08/05/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
08/05/202413:00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
14/03/202412:00GlobeNewswire Inc.Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesNASDAQ:KROSKeros Therapeutics Inc
06/03/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
05/03/202413:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
05/03/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
05/03/202413:00GlobeNewswire Inc.Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KROSKeros Therapeutics Inc
28/02/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
28/02/202421:01GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
23/02/202422:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
16/02/202401:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
16/02/202401:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KROS

Your Recent History

LSE
ALTN
Altyngold
LSE
AAZ
Anglo Asian Mining
LSE
JSE
Jadestone Energy
LSE
POS
Plexus
LSE
EQLS
Equals
LSE
STX
Shield Therapeutics
LSE
VAST
Vast Resources
LSE
GGP
Greatland Gold
LSE
GKP
Gulf Keystone Petroleum
LSE
ENET
Ethernity Networks
LSE
ECR
Ecr Minerals
LSE
STAF
Staffline
LSE
BARC
Barclays
LSE
CPI
Capita
LSE
ADIG
Abrdn Diversified Income...
LSE
SQZ
Serica Energy
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved